Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab

被引：0
|
作者：
Khan, M. [1 ]
Heetun, Z. [1 ]
Moloney, J. [1 ]
Courtney, G. [1 ]
Aftab, A. R. [1 ]
机构：
[1] St Lukes Hosp, Kilkenny, Kilkenny, Ireland
来源：
IRISH JOURNAL OF MEDICAL SCIENCE | 2015年 / 184卷
关键词：
THERAPY; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5 (14S114)
引用
收藏
页码：S73 / S74
页数：2
相关论文
共 50 条
  • [31] Autonomic Dysfunctions in Patients with Inflammatory Bowel Disease in Clinical Remission
    Sharma, Purnima
    Makharia, Govind K.
    Ahuja, Vineet
    Dwivedi, Sada Nand
    Deepak, Kishore Kumar
    DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (04) : 853 - 861
  • [32] Influence of initial albumin levels on infliximab and adalimumab trough levels in inflammatory bowel disease patients
    Gonzalez-Lopez, J.
    Llamas, C.
    Giraldez-Montero, J. M.
    Ferreiro, R.
    Baston, I.
    Lamas, M. J.
    Dominguez-Munoz, J. E.
    Barreiro-de Acosta, M.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S248 - S249
  • [33] The Effect of Infliximab and Adalimumab Treatment on Angiogenic Factor Levels in Patients With Inflammatory Bowel Disease (IBD)
    Algaba, Alicia
    Linares, Pablo M.
    Contreras, Maria Encarnacion Fernandez
    Figuerola, Ariadna
    Calvet, Xavier
    Guerra, Ivan
    Villa, Jose Carlos
    Chaparro, Maria
    Agullo, Jose Luis Rodriguez
    Gisbert, Javier P.
    Bermejo, Fernando
    GASTROENTEROLOGY, 2012, 142 (05) : S869 - S870
  • [34] PRESENCE OF ANTIBODIES TO ADALIMUMAB AND INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN CLINICAL REMISSION
    Eng, G.
    Fana, V.
    Omerovic, E.
    Hojsgaard, P.
    Lindegaard, H. M.
    Jensen, E. K.
    Bouchelouche, P. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 230 - 230
  • [35] Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease
    Fernandes, Samuel Raimundo
    Rodrigues, Ines Coelho
    Serrazina, Juliana
    Botto, Ines Ayala
    Bernardo, Sonia
    Goncalves, Ana Rita
    Valente, Ana
    Santos, Paula Moura
    Correia, Luis Araujo
    Marinho, Rui Tato
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (10) : 1202 - 1208
  • [36] Switching to Subcutaneous Infliximab Maintenance Therapy Is Effective in Patients with Inflammatory Bowel Disease
    Rautakorpi, Jaakko
    Kolehmainen, Sara
    Loyttyniemi, Eliisa
    af Bjorkesten, Clas-Goran
    Arkkila, Perttu
    Sipponen, Taina
    Salminen, Kimmo
    DIGESTIVE DISEASES AND SCIENCES, 2025, : 1457 - 1466
  • [37] Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study
    Steenholdt, Casper
    Molazahi, Akbar
    Ainsworth, Mark Andrew
    Brynskov, Jorn
    Thomsen, Ole Ostergaard
    Seidelin, Jakob Benedict
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2012, 47 (05) : 518 - 527
  • [38] Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?
    Serra, K.
    Rodriguez-Alonso, L.
    Padulles, N.
    Rodriguez-Moranta, F.
    Arajol, C.
    Gilabert, P.
    Rodriguez, R.
    Bas, J.
    Morandeira-Rego, F.
    Santacana, E.
    Padulles, A.
    Guardiola, J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S358 - S358
  • [39] Anti-TNF, Infliximab, and Adalimumab Can Be Effective in Eosinophilic Bowel Disease
    Turner, Dan
    Wolters, Victorien M.
    Russell, Richard K.
    Shakhnovich, Valentina
    Muise, Aleixo M.
    Ledder, Oren
    Ngan, Bo
    Friesen, Craig
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2013, 56 (05): : 492 - 497
  • [40] Infliximab pharmacokinetics in inflammatory Bowel disease patients
    Ternant, David
    Aubourg, Alexandre
    Magdelaine-Beuzelin, Charlotte
    Degenne, Danielle
    Watier, Herve
    Picon, Laurence
    Paintaud, Gilles
    THERAPEUTIC DRUG MONITORING, 2008, 30 (04) : 523 - 529
12345